These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17164314)

  • 21. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
    Michalská D; Stepan JJ; Basson BR; Pavo I
    J Clin Endocrinol Metab; 2006 Mar; 91(3):870-7. PubMed ID: 16352692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
    Zegels B; Eastell R; Russell RG; Ethgen D; Roumagnac I; Collette J; Reginster JY
    Bone; 2001 Jan; 28(1):108-12. PubMed ID: 11165950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
    Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Increase of PTH in post-menopausal osteoporosis].
    Cerdà D; Peris P; Monegal A; Albaladejo C; Martínez de Osaba MJ; Surís X; Guañabens N
    Rev Clin Esp; 2011; 211(7):338-43. PubMed ID: 21596374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infusions of parathyroid hormone in ruminants: hypercalcemia and reduced plasma 1,25-dihydroxyvitamin D concentrations.
    Hove K; Horst RL; Littledike ET; Beitz DC
    Endocrinology; 1984 Mar; 114(3):897-903. PubMed ID: 6546544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.
    Makras P; Polyzos SA; Papatheodorou A; Kokkoris P; Chatzifotiadis D; Anastasilakis AD
    Clin Endocrinol (Oxf); 2013 Oct; 79(4):499-503. PubMed ID: 23452098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
    Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
    Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis.
    Horowitz M; Wishart JM; Need AG; Morris HA; Nordin BE
    Clin Endocrinol (Oxf); 1993 Dec; 39(6):649-55. PubMed ID: 8287582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium and vitamin d supplementation in postmenopausal women.
    Aloia JF; Dhaliwal R; Shieh A; Mikhail M; Islam S; Yeh JK
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1702-9. PubMed ID: 24064695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
    Black DM; Bilezikian JP; Ensrud KE; Greenspan SL; Palermo L; Hue T; Lang TF; McGowan JA; Rosen CJ;
    N Engl J Med; 2005 Aug; 353(6):555-65. PubMed ID: 16093464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
    Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?
    Doggrell SA
    Expert Opin Pharmacother; 2004 Apr; 5(4):955-8. PubMed ID: 15102578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
    Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
    Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.